SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
暂无分享，去创建一个
S. Peters | C. Britschgi | D. Betticher | M. Joerger | S. Rothschild | A. Zippelius | A. Ochsenbein | M. Pless | P. Froesch | N. Mach | S. Savic | W. Janthur | Michel Gonzalez | C. Rusterholz | M. Mark | M. Frueh | E. Eboulet | A. Bettini | C. Waibel | G. Godar